Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. - Wikidata - awgldk - TriplyDB

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.

http://www.wikidata.org/entity/Q44649979

about

Aripiprazole versus placebo for schizophrenia Antipsychotic medication for early episode schizophrenia Aripiprazole versus typical antipsychotic drugs for schizophrenia Aripiprazole versus typicals for schizophrenia Aripiprazole for schizophrenia Aripiprazole for schizophrenia Aripiprazole alone or in combination for acute mania Aripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review The cytokine model of schizophrenia: emerging therapeutic strategies Review of depot aripiprazole for schizophrenia World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163).The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole.Aripiprazole for late-life schizophrenia Efficacy and tolerability of aripiprazole: a 26-week switching study from oral antipsychotics.A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting.The 2nd Schizophrenia International Research Society Conference, 10-14 April 2010, Florence, Italy: summaries of oral sessions.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.Aripiprazole: pharmacology, efficacy, safety and tolerability.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Almost all antipsychotics result in weight gain: a meta-analysis.Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study Aripiprazole versus haloperidol treatment in early-stage schizophrenia.A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder.Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics Aripiprazole: the evidence of its therapeutic impact in schizophrenia Teaching trainees to negotiate research collaborations with industry: a mentorship model.Role of aripiprazole in treatment-resistant schizophrenia.Partial dopamine agonists in schizophrenia.A review of pharmacologic strategies for switching to atypical antipsychotics The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders.The metabolic effects of antipsychotic medications.Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.

P2860

Q24234961-2C7D9AFA-7429-4B68-BA36-C98F77542511 Q24236683-9D96CA93-892A-46C4-BD37-814E8462CDBD Q24241974-78A65D16-503D-486D-AA56-FE3C7B06B59F Q24242810-C4C476FF-2923-4CE5-88CE-CE0D0CB6F07E Q24246298-F3FC19CB-7F38-47B1-ABF0-A50F471F15D9 Q24247235-0B83BA1E-EE2E-4F73-A371-234F39A16768 Q24247531-A2C997F8-9B56-4B62-ACB4-EBEF24895CFB Q24615556-7DD331E0-11DB-41A5-B4C7-DFB79974D064 Q26770497-2CA73CC4-5FAF-4811-B453-C600B165C6D8 Q26865996-E4383BD3-67C0-4C72-B8B7-42E66B69BA03 Q27008464-DA9938C7-D3A5-4B30-ACF2-F84243824D92 Q33223628-1BA94713-A442-476E-A5FE-9EB4C29E4AE6 Q33235110-8EBCEBA1-8C60-4F28-B40A-CFE3457DCD94 Q33518314-E17559B4-9829-4020-BF5F-63238209FF0D Q33587032-28D44B7F-3685-4EE1-B282-D8BD29FC4F05 Q33619940-3080E0C5-CB79-4CBC-B89D-138CFCEF4D5A Q33755676-222DF1BC-C805-4AF9-B618-1ACAE1BED33F Q34121832-5B282307-79A4-492A-9B2F-79370A29E9DE Q34165051-EE93C4B9-91FF-4A07-B69E-AE82BFEC118F Q34174609-4AF859C8-EDE1-4973-9369-901FF63058A2 Q34279073-ADBBDFEC-BC7D-4664-91D2-9D0E5BA99CA6 Q34315836-C5FD68C3-88B2-448F-AA33-40D51CE705AB Q34338202-C1991D57-7104-490F-BC2D-C79C9ECF1E61 Q34486175-79022207-6AC2-4428-9325-AAE5C4F60783 Q34558285-7DCCB8C7-9157-48E3-8F4B-34A7C606EEFE Q34640811-07D9FA36-C9F2-4D41-AF6A-48411BB8AE41 Q34661499-E62E7EFA-375D-459C-94C8-77255E17BBB7 Q35062881-50104587-5A9F-40E2-9915-59DE5204B6A8 Q35191252-5C8972FD-9310-4385-83CF-F5914376F750 Q35684487-FF613413-1A24-40CC-B688-97870C42D668 Q35833294-2168144C-162B-406A-B11C-B8C383163C55 Q35873789-CE80F05B-5DC4-4E74-81E2-1EE3D395A661 Q35876413-50F29BD5-F00A-4942-BEAC-731420744430 Q35920534-09B7B7FE-983C-4C76-8AD8-AAAD99150A3C Q36026776-56D8EA30-C82A-482E-9F9A-90EA1C031670 Q36141833-78DF93A9-EA5B-4DF0-8870-835A41B909BE Q36199687-7D6875F7-1F9D-4E42-8937-D8B31D994FBB Q36321595-EA65AF5C-BB4C-4F8F-8E5B-33E3384D5847 Q36577856-F11434C4-A8CF-4C52-A4F5-714FEB430E57 Q36626247-2A0D38D4-BC0D-4AD3-A5B7-C55A293B1EF9

P2860

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.

http://www.wikidata.org/entity/Q44649979

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Efficacy and safety of aripipr ...... cute relapse of schizophrenia.

@en

Efficacy and safety of aripipr ...... cute relapse of schizophrenia.

@nl

type

label

Efficacy and safety of aripipr ...... cute relapse of schizophrenia.

@en

Efficacy and safety of aripipr ...... cute relapse of schizophrenia.

@nl

prefLabel

Efficacy and safety of aripipr ...... cute relapse of schizophrenia.

@en

Efficacy and safety of aripipr ...... cute relapse of schizophrenia.

@nl

P1433

Q44649979-6515A033-A04C-4E8B-9F25-F43B21BED91A

P1476

Q44649979-820D002C-FE30-46C6-9A79-E81C05BE10B1

P2093

Q44649979-4E696E95-EC1A-445B-B6CD-772C0FA95D10

Q44649979-B5B7DA2C-C3C3-40D4-9FD9-D741491565E2

Q44649979-C2A524BF-A75E-45B0-B79B-32F98833524B

Q44649979-D9BCC0F6-2B19-4DE7-915C-5C48323243C4

Q44649979-E4E882BD-3A5C-4217-9D14-A9AE5E9F54AA

Q44649979-E79A7C02-E147-408C-990E-5BCAFA36E252

Q44649979-E8478BA7-9837-456C-B798-D395EB731C8D

Q44649979-F0A439C3-088E-459A-A0C6-4ADC51F79EE2

Q44649979-F15925AA-0677-4AA1-A156-BD0CBEAE0C8A

P304

Q44649979-22830EB4-4AF7-4BC0-B363-D6EEDE55F296

P31

Q44649979-AA97E5D8-FB82-4164-8739-BA76C33C58F8

P356

Q44649979-B292518A-7C6B-4535-82BD-D17BFEA7E7D8

P433

Q44649979-E4AC1723-5915-4537-8981-05DF9F254A62

P478

Q44649979-B5746F31-029A-446B-B8FD-FE1A5B6C3306

P50

Q44649979-14174FEA-FB99-4C71-AB65-A56BCD9E952F

P577

Q44649979-3F1EF740-43E5-4195-B8F8-BA769771092C

P698

Q44649979-70196FA9-F163-4A8D-8E6E-9E7FEEE4F01F

P921

Q44649979-BCF89176-0D29-43AB-8FB8-1BBD3A23A73C

P356

S1461145703003651

P1433

The International Journal of Neuropsychopharmacology

P1476

Efficacy and safety of aripipr ...... cute relapse of schizophrenia.

@en

P2093

Anutosh Saha

http://www.w3.org/2001/XMLSchema#string

Donald Archibald

http://www.w3.org/2001/XMLSchema#string

Gary Ingenito

http://www.w3.org/2001/XMLSchema#string

Mark N Lerman

http://www.w3.org/2001/XMLSchema#string

Mirza Ali

http://www.w3.org/2001/XMLSchema#string

Robert D McQuade

http://www.w3.org/2001/XMLSchema#string

Ronald Marcus

http://www.w3.org/2001/XMLSchema#string

Teresa Pigott

http://www.w3.org/2001/XMLSchema#string

William H Carson

http://www.w3.org/2001/XMLSchema#string

P304

325-337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1017/S1461145703003651

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Siegfried Kasper

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14609439

http://www.w3.org/2001/XMLSchema#string

P921